DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
PTI-428 is an investigational drug.
There have been 22 clinical trials for PTI-428. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2016.
The most common disease conditions in clinical trials are Fibrosis, Cystic Fibrosis, and Alzheimer Disease. The leading clinical trial sponsors are Proteostasis Therapeutics, Inc., Pain Therapeutics, and Cassava Sciences, Inc.
Recent Clinical Trials for PTI-428
|A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema||Hoffmann-La Roche||Phase 3|
|PTI-125, 100 mg, for Mild-to-moderate Alzheimer's Disease Patients||National Institute on Aging (NIA)||Phase 2|
|PTI-125, 100 mg, for Mild-to-moderate Alzheimer's Disease Patients||Cassava Sciences, Inc.||Phase 2|